PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) announced that its management team will participate in two upcoming investor conferences in February and March, where executives will deliver presentations and meet with investors.
The company said management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 8:40 a.m. Eastern Time. The event will be held virtually.
Passage Bio management is also scheduled to present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:50 p.m. Eastern Time in Boston.
A live webcast of the presentations will be available in the Investors & Media section of the company’s website at investors.passagebio.com. A replay will remain accessible for 30 days following each event.
Passage Bio is a clinical-stage biotechnology company developing genetic medicines for neurodegenerative diseases. Its lead product candidate, PBFT02, is being developed to treat conditions including frontotemporal dementia by increasing progranulin levels to restore lysosomal function and potentially slow disease progression.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.